Company Description
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases.
It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.
The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease.
It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 16, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Francisco Salva |
Contact Details
Address: 21 Business Park Drive Branford, Connecticut 06405 United States | |
| Phone | 203 646 6446 |
| Website | azitrainc.com |
Stock Details
| Ticker Symbol | AZTR |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001701478 |
| CUSIP Number | 05479L104 |
| ISIN Number | US05479L1044 |
| Employer ID | 46-4478536 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Francisco D. Salva | President, Chief Executive Officer and Director |
| Travis M. Whitfill M.P.H., Ph.D. | Co-Founder, Chief Operating Officer, Secretary and Director |
| Norman Staskey | Chief Financial Officer and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 24, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 10-K | Annual Report |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 6, 2025 | 8-K | Current Report |
| Feb 6, 2025 | 8-K | Current Report |
| Feb 5, 2025 | 424B5 | Filing |
| Jan 16, 2025 | 8-K | Current Report |
| Jan 16, 2025 | 424B5 | Filing |
| Jan 14, 2025 | 424B3 | Prospectus |